

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Patent Application of:

William R. Moyle and Yongna Xing

Group Art Unit: Unknown

Serial No: 10/797,553

Examiner: Unknown

Filed: March 10, 2004

For: Protein Knobs

Mail Stop Missing Parts Commissioner for Patents P.O. Box for Patents Alexandria, VA 22313-1450

SUPPLEMENTARY AMENDMENT PURSUANT TO 37 C.F.R. SECTION 1.115

This Supplementary Amendment pursuant to 37 C.F.R. Section 1.115 is in response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Sequence Disclosures in the above-identified patent application.

Applicant requests that the Examiner consider the following amendments and response and pass the above-identified application to issue.

Kindly amend the subject application as follows:

CERTIFICATE OF MAILING TO 37 C.F.R. SECTION 1.8

I hereby certify that this correspondence is being deposited, pursuant to 37 C.F.R. Section 1.8, with the United States

Diane Cuddemi

William R. Moyle and Yongna Xing

Serial No: 10/797,553 Filed: March 10, 2004

Page 2

RESPONSE

As set out above, applicant has submitted this Supplementary Amendment in response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Sequence Disclosures in the above-identified patent application.

In response to this Notice, applicant has submitted herewith a revised Sequence Listing of the nucleotide and/or amino acid sequences in the above-identified patent application on paper copy in accord with 37 C.F.R. Section 1.821(c) and in computer readable form in accord with 37 C.F.R. Section 1.821(e). Applicant has also filed herewith a statement pursuant to 37 C.F.R. Section 1.821(f) that the content of the paper copy and computer readable copy are the same and a statement pursuant to 37 C.F.R. Section 1.821(g) that the submission of the paper copy and the computer readable copy includes no new matter.

In accordance with 37 C.F.R. Sections 1.821(c) and 1.821(d), applicant has already provided in the specification references to each sequence disclosed in the Sequence Listing by use of the separate identifiers written as SEQ ID NO:1, SEQ ID NO:2, etc.

In view of the foregoing amendments and response, applicant requests allowance of the claims pending in this application. Applicant requests the Examiner to telephone the undersigned attorney should the Examiner have any questions or comments which might be most expeditiously handled by telephone conference.

Applicants' attorney authorizes the Examiner to charge Deposit Account 501365 if there are any additional charges in connection with this response and amendment.

Respectfully submitted,

Ctu D

Steven A. Bossone, Ph.D. Reg. No. 51,196

Date: August 24,2005

Direct communications to:

Steven A. Bossone, Ph.D. Serono Research Institute One Technology Place Rockland, MA 02370